449 related articles for article (PubMed ID: 30837203)
1. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Nasrallah HA; Fedora R; Morton R
Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
[TBL] [Abstract][Full Text] [Related]
2. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Panchal SC; Ondo WG
Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
[TBL] [Abstract][Full Text] [Related]
3. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
4. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
5. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
6. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Sahli ZT; Tarazi FI
Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin: First Global Approval.
Markham A
Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680
[TBL] [Abstract][Full Text] [Related]
9. Pimavanserin for the treatment of Parkinson's disease psychosis.
Chendo I; Ferreira JJ
Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
[TBL] [Abstract][Full Text] [Related]
10. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
11. Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
[TBL] [Abstract][Full Text] [Related]
12. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
[TBL] [Abstract][Full Text] [Related]
13. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
Ballard C; Youakim JM; Coate B; Stankovic S
J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
[TBL] [Abstract][Full Text] [Related]
14. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
[TBL] [Abstract][Full Text] [Related]
15. Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication.
Davis J; Zamora D; Horowitz M; Leucht S
Expert Opin Pharmacother; 2021 Sep; 22(13):1651-1660. PubMed ID: 34404290
[No Abstract] [Full Text] [Related]
16. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Norton JC; Chi-Burris K; Demos G
CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
18. Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series.
Rothenberg KG; McRae SG; Dominguez-Colman LM; Shutes-David A; Tsuang DW
Am J Case Rep; 2023 Sep; 24():e939806. PubMed ID: 37775968
[TBL] [Abstract][Full Text] [Related]
19. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
20. Pimavanserin.
Hunter NS; Anderson KC; Cox A
Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
